July 2026 Biotech Catalysts: 10 FDA Dates & Phase 3 Readouts

PDUFA decision for brensocatib in bronchiectasis

Brensocatib · Non-cystic fibrosis bronchiectasis

Insmed's DPP1 inhibitor brensocatib is up for FDA approval in non-CF bronchiectasis — a chronic lung condition with no approved therapy and 350,000+ US patients. Approval transforms Insmed from a single-product Arikayce company into a multi-billion dollar respiratory franchise.

Phase 3 ASPEN met its primary endpoint with statistically significant reduction in pulmonary exacerbations. Approval probability is very high. Stock likely up 15-25% on approval, down 35-50% on CRL. The post-approval launch trajectory is the multi-year story.

PDUFA decision for volixibat in PFIC

Volixibat · Progressive familial intrahepatic cholestasis (PFIC)

Mirum extends its rare cholestatic liver disease franchise with volixibat in PFIC. Approval gives Mirum a second commercial asset alongside Livmarli and a durable revenue base in pediatric rare liver disease.

Approval likely. Stock impact moderate single-day; meaningful for franchise breadth and post-Livmarli growth narrative.

Phase 3 SKYSCRAPER-01 OS update for tiragolumab in NSCLC

Tiragolumab · First-line PD-L1 high NSCLC

Roche's TIGIT inhibitor tiragolumab gets a final overall survival readout in lung cancer after multiple prior misses across the TIGIT class. A positive OS result would be a major comeback for TIGIT as an immuno-oncology mechanism.

TIGIT class has had repeated setbacks (Merck's vibostolimab, Gilead's domvanalimab). Probability of OS hit is low (~25-30%). A positive result reopens TIGIT investment across the sector.

PDUFA decision for trofinetide label expansion in adult Rett syndrome

Daybue (trofinetide) · Adult Rett syndrome

Acadia seeks adult Rett syndrome approval to extend Daybue beyond its current pediatric label. Adult approval expands Daybue's TAM and helps offset the post-Nuplazid generic erosion.

Approval probability moderate. Phase 3 LILAC-2 data was supportive. A clean approval extends the Daybue franchise meaningfully.

PDUFA decision for UX111 in MPS IIIA (Sanfilippo A)

UX111 (AAV9 SGSH gene therapy) · MPS IIIA / Sanfilippo syndrome type A

Ultragenyx seeks accelerated approval for UX111, an AAV gene therapy for a fatal pediatric lysosomal storage disease with no approved treatment. Approval would be the first-ever therapy for Sanfilippo A and a major credibility win for Ultragenyx's gene therapy platform.

Approval is by no means guaranteed; FDA has been skeptical of small datasets in pediatric AAV programs post-Elevidys. Approval up 30-50%; CRL down 25-40%. Probability ~50/50.

Phase 3 ARISE topline data for KarXT in Alzheimer's psychosis

Cobenfy (KarXT) · Alzheimer's-related psychosis

BMY tests its Karuna acquisition Cobenfy in Alzheimer's psychosis. Acadia's Nuplazid failed the analogous trial; BMY's M1/M4 muscarinic mechanism is different. Approval would be a major new indication for the $14B Karuna acquisition.

Primary endpoint is psychosis symptom reduction at week 12. A clean win adds $2-4B in peak sales potential to Cobenfy and validates the Karuna deal. A miss puts pressure on BMY's neuro pipeline narrative.

Phase 3 EVOLVE Phase 3 topline data for sepiapterin in PKU

Sepiapterin · Phenylketonuria (PKU)

PTC's oral BH4 precursor sepiapterin targets the BH4-responsive PKU population. Approval would establish a multi-hundred-million dollar franchise and validate PTC's strategic pivot after the Translarna setbacks.

Primary endpoint is phenylalanine reduction versus placebo. Phase 2 data was strong. A clean readout supports a 2026 NDA filing.

PDUFA decision for sparsentan label expansion in FSGS

Filspari (sparsentan) · Focal segmental glomerulosclerosis (FSGS)

Travere seeks full FSGS approval for Filspari. The drug already has full IgA nephropathy approval; FSGS approval roughly doubles the franchise opportunity and adds a defensive moat against incoming kidney disease entrants.

Approval probability is ~60%. Phase 3 DUPLEX data on the proteinuria endpoint was supportive but the kidney function endpoint was less clear. CRL likely costs 25-35% on TVTX.

Phase 2 SOLSTICE topline data for tobevibart + elebsiran in chronic hepatitis B

Tobevibart + elebsiran combination · Chronic hepatitis B (functional cure)

Vir tests its combination siRNA + neutralizing antibody approach for functional cure of chronic hepatitis B. A meaningful functional cure rate would be transformative for a market with ~300M global patients and limited current options.

Functional cure rate (sustained HBsAg loss) versus standard of care. A cure rate above 25% would be a major positive signal. Most prior HBV cure programs have disappointed.

Phase 2 topline data for tegavivint in CTNNB1-mutant solid tumors

Tegavivint · Beta-catenin mutant solid tumors

Iterion's small molecule Wnt pathway inhibitor tegavivint reports its first meaningful efficacy readout in a precision-defined patient population. Beta-catenin mutations are a recognized resistance driver across multiple solid tumors with no approved targeted options.

Watch for objective response rate, disease control rate, and durability. Even modest activity in a defined biomarker population supports a Phase 3 pathway.